• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Humoral response after SARS-CoV-2 booster vaccination in haemodialysis patients with and without prior infection.

作者信息

Füessl Louise, Lau Tobias, Rau Simon, Regenauer Ron, Paal Michael, Hasmann Sandra, Arend Florian M, Bruegel Mathias, Teupser Daniel, Fischereder Michael, Schönermarck Ulf

机构信息

Department of Medicine IV, University Hospital of Munich, Munich, Germany.

Dialysezentrum Bad Tölz und Wolfratshausen, Bad Tölz,Germany.

出版信息

Clin Kidney J. 2022 May 24;15(8):1633-1635. doi: 10.1093/ckj/sfac148. eCollection 2022 Aug.

DOI:10.1093/ckj/sfac148
PMID:35892016
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9308091/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f40/9308091/374b504d37b6/sfac148fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f40/9308091/7628318e667f/sfac148fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f40/9308091/374b504d37b6/sfac148fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f40/9308091/7628318e667f/sfac148fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f40/9308091/374b504d37b6/sfac148fig2.jpg

相似文献

1
Humoral response after SARS-CoV-2 booster vaccination in haemodialysis patients with and without prior infection.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）加强疫苗接种后，有或无既往感染的血液透析患者的体液免疫反应
Clin Kidney J. 2022 May 24;15(8):1633-1635. doi: 10.1093/ckj/sfac148. eCollection 2022 Aug.
2
Antibody response to mRNA SARS-CoV-2 vaccines in haemodialysis patients.血液透析患者对SARS-CoV-2 mRNA疫苗的抗体反应。
Clin Kidney J. 2021 Jul 6;14(10):2234-2238. doi: 10.1093/ckj/sfab127. eCollection 2021 Oct.
3
Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.妊娠期 2019 年冠状病毒病（COVID-19）疫苗接种、严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染史和疫苗加强剂与分娩时母婴抗体水平的关系。
Obstet Gynecol. 2022 Mar 1;139(3):373-380. doi: 10.1097/AOG.0000000000004693.
4
Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients.接种疫苗的肾移植和血液透析患者中严重突破性 SARS-CoV-2 感染的发生率。
J Nephrol. 2022 Apr;35(3):769-778. doi: 10.1007/s40620-022-01257-5. Epub 2022 Feb 21.
5
SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies.SARS-CoV-2 感染和疫苗接种引发具有增强策略意义的长寿 B 和 CD4+ T 淋巴细胞。
J Clin Invest. 2022 Mar 15;132(6). doi: 10.1172/JCI157990.
6
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.抗肿瘤治疗的癌症患者接种 BNT162b2 冠状病毒病 2019 信使 RNA 疫苗后体液免疫应答降低。
ESMO Open. 2021 Oct;6(5):100274. doi: 10.1016/j.esmoop.2021.100274. Epub 2021 Sep 8.
7
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.针对多发性硬化症患者的 SARS-CoV-2 灭活疫苗和 mRNA 疫苗的安全性和体液免疫应答率。
Mult Scler Relat Disord. 2022 Mar;59:103690. doi: 10.1016/j.msard.2022.103690. Epub 2022 Feb 13.
8
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.SARS-CoV-2-mRNA 加强疫苗接种逆转免疫功能低下患者的无反应性和早期抗体衰减 - 一项比较实体瘤、多发性骨髓瘤和炎症性肠病患者免疫反应的四期研究。
Front Immunol. 2022 May 12;13:889138. doi: 10.3389/fimmu.2022.889138. eCollection 2022.
9
Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection.对有和无SARS-CoV-2感染史的秘鲁医护人员进行间隔7个月的BBIBP-CorV和BNT162b2异源疫苗接种后体液免疫反应的评估。
Vaccines (Basel). 2022 Mar 24;10(4):502. doi: 10.3390/vaccines10040502.
10
Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response.Moderna mRNA-1273加强疫苗对体液免疫反应丧失后的全程接种高危慢性透析患者的影响
Vaccines (Basel). 2022 Apr 11;10(4):585. doi: 10.3390/vaccines10040585.

引用本文的文献

1
Comparison of Humoral Response between Third and Fourth Doses of COVID-19 Vaccine in Hemodialysis Patients.血液透析患者中新冠疫苗第三剂和第四剂体液免疫反应的比较
Vaccines (Basel). 2023 Oct 12;11(10):1584. doi: 10.3390/vaccines11101584.
2
Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study.印度尼西亚日惹地区接受血液透析的终末期肾病患者中 COVID-19 BNT162b2 加强疫苗的免疫原性和安全性：一项队列前瞻性研究。
BMC Nephrol. 2023 May 30;24(1):151. doi: 10.1186/s12882-023-03218-x.
3
Increasing but insufficient neutralizing activity against Omicron-BA.1 after a second booster dose of mRNA-1273 vaccine in chronic haemodialysis patients.

本文引用的文献

1
Diminished Short- and Long-Term Antibody Response after SARS-CoV-2 Vaccination in Hemodialysis Patients.血液透析患者接种新型冠状病毒 2 型疫苗后短期和长期抗体反应减弱。
Vaccines (Basel). 2022 Apr 13;10(4):605. doi: 10.3390/vaccines10040605.
2
Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients.血液透析患者接种三剂mRNA-1273或BNT162b2新冠病毒疫苗后的体液免疫反应
Vaccines (Basel). 2022 Mar 27;10(4):522. doi: 10.3390/vaccines10040522.
3
Humoral response after a fourth "booster" dose of a Coronavirus disease 2019 vaccine following a 3-dose regimen of mRNA-based vaccination in dialysis patients.
慢性血液透析患者在第二次接种mRNA-1273疫苗加强针后，对奥密克戎-BA.1的中和活性增加但仍不足。
Clin Kidney J. 2022 Sep 16;15(12):2346-2348. doi: 10.1093/ckj/sfac211. eCollection 2022 Dec.
4
SARS-CoV-2 vaccination in haemodialysis patients: Insides from a prospective study comparing mRNA and viral vector vaccines.血液透析患者中的新型冠状病毒2型疫苗接种：一项比较信使核糖核酸疫苗和病毒载体疫苗的前瞻性研究内情
Lancet Reg Health Eur. 2022 Sep 13;21:100491. doi: 10.1016/j.lanepe.2022.100491. eCollection 2022 Oct.
在透析患者中，基于mRNA的疫苗接种3剂方案后，接种第4剂2019冠状病毒病疫苗“加强针”后的体液免疫反应。
Kidney Int. 2022 Jun;101(6):1289-1290. doi: 10.1016/j.kint.2022.04.006. Epub 2022 Apr 12.
4
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.在全国范围内接种第四剂 BNT162b2 mRNA 新冠疫苗。
N Engl J Med. 2022 Apr 28;386(17):1603-1614. doi: 10.1056/NEJMoa2201688. Epub 2022 Apr 13.
5
Seroresponse to Third Doses of SARS-CoV-2 Vaccine Among Patients Receiving Maintenance Dialysis.接受维持性透析患者对SARS-CoV-2疫苗第三剂的血清反应。
Am J Kidney Dis. 2022 Jul;80(1):151-153. doi: 10.1053/j.ajkd.2022.03.002. Epub 2022 Apr 1.
6
Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose.维持性透析患者接种新冠病毒mRNA疫苗后体液免疫反应减弱及补充第三剂后的恢复情况
Vaccines (Basel). 2022 Mar 11;10(3):433. doi: 10.3390/vaccines10030433.
7
Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients.在血液透析患者中，第三次接种 BNT162b2 疫苗前后对 B.1.617.2（德尔塔）变异株的中和抗体活性。
Front Immunol. 2022 Mar 4;13:840136. doi: 10.3389/fimmu.2022.840136. eCollection 2022.
8
Inferior humoral and sustained cellular immunity against wild-type and omicron variant of concern in hemodialysis patients immunized with 3 SARS-CoV-2 vaccine doses compared with 4 doses.与接种4剂相比，接种3剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的血液透析患者对野生型和奥密克戎变异株的体液免疫较低，细胞免疫持续存在。
Kidney Int. 2022 Jun;101(6):1287-1289. doi: 10.1016/j.kint.2022.03.005. Epub 2022 Mar 14.
9
Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost.血液透析患者接种mRNA-BNT162b2疫苗6个月后体液免疫反应减弱：是时候加强接种了。
Kidney Int. 2021 Dec;100(6):1334-1335. doi: 10.1016/j.kint.2021.10.006. Epub 2021 Oct 14.
10
Antibody response to mRNA SARS-CoV-2 vaccines in haemodialysis patients.血液透析患者对SARS-CoV-2 mRNA疫苗的抗体反应。
Clin Kidney J. 2021 Jul 6;14(10):2234-2238. doi: 10.1093/ckj/sfab127. eCollection 2021 Oct.